Global Radiopharmaceuticals Market 2026 Industry Size, Growth, Opportunities, Outlook and Forecast,the key players are: Cardinal Health, Mallinckrodt., General Electric Company, Lantheus Medical Imaging, Inc., Bayer AG, Nordion (Canada) Inc.

The Global Radiopharmaceuticals Market report includes historic data with forecast years from 2019-2026. The global radiopharmaceuticals market is expected to rise to an estimated value of USD 11.85 billion by 2026 registering a substantial CAGR of 9.30% in the forecast period of 2019-2026 by major market competitors like Cardinal Health, Mallinckrodt., General Electric Company, Lantheus Medical Imaging, Inc., Bayer AG etc.

Global Radiopharmaceuticals Market report includes competitive developments such as expansions, agreements, new product launches, and acquisitions, mergers in the market.it Strategically outline the key players in the market and extensively analyze their growth strategies.

Click the link to Get a Free Sample Copy of the Report @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-radiopharmaceuticals-market

Global Radiopharmaceuticals Market segmented By Type ,Application , Procedural Volumes , End User ,Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

In the rise in market can be attributed to increasing prevalence of cancer and cardiovascular chronic diseases, rising health expenditure and technological advancements.

Major Market Competitors: Few of the major market competitors currently working in the radiopharmaceuticals market are

Cardinal Health, Mallinckrodt., General Electric Company, Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.p.A., Nordion (Canada) Inc., Advanced Accelerator Applications, Surgery Theater, Positron Corporation, NTP, IsoPET, Eli Lilly and Company., Jubilant Pharma. LLC, Actinium Pharmaceuticals, Inc., Immunomedics, Inc., Areva Pharma, Merck & Co., Inc., Navidea Biopharmaceuticals, Inc., Eckert & Ziegler., Siemens Healthcare Private Limited, Novartis AG, Curium, among others.

Key Developments in the Market:

• In April 2018, Cyclopharma has entered into an agreement to sell all its radiopharmaceutical manufacturing and commercialization activities to Curium. With this acquisition, Curium would be able to expand its manufacturing, development and designs of new compounds, thereby expanding its radiopharmaceutical business to soon become a world leader

• In January 2018, Advanced Accelerator Application (AAA) received the permission from USA’s FDA to use Lutathera for treating a type of cancer which affects pancreas/ gastrointestinal tract i.e. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs). This is the very first time approval has been given to use a radiopharmaceutical for treating GEP-NETs. Thus, with this approval, radiopharmaceuticals have now been approved to treat a whole new disease, thereby expanding its market, which would significantly contribute towards the growth of radiopharmaceuticals market globally in the forecasted period

Competitive Analysis:

Global radiopharmaceuticals market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of radiopharmaceuticals for Global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Table of Contents:

Chapter 1: Study Coverage
Chapter 2: Executive Summary
Chapter 3: Global Radiopharmaceuticals Market Size-by Manufacturers
Chapter 4: Radiopharmaceuticals Production-by Regions
Chapter 5: Radiopharmaceuticals Consumption-by Regions
Chapter 6: Global Radiopharmaceuticals Market Size-by Type
Chapter 7: Global Radiopharmaceuticals Market Size-by Application
Chapter 8: Manufacturers Profiles
Chapter 9: Production Forecasts
Chapter 10: Consumption Forecast
Chapter 11: Upstream, Industry Chain and Downstream Customers Analysis
Chapter 12: Opportunities & Challenges, Threat and Affecting Factors
Chapter 13: Key Findings
Chapter 14: Appendix

Request Complete TOC Of this Report @ https://databridgemarketresearch.com/toc/?dbmr=global-radiopharmaceuticals-market

Market Segmentation:Global Radiopharmaceuticals Market segmented By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine),

By Application

• Diagnostic Applications
o Spect Applications
 Cardiology
 Lymphoma
 Neurology
 Thyroid
 Other Spect Applications
o Pet Applications
 Oncology
 Cardiology
 Neurology
 Other Pet Applications
• Therapeutic Applications
o Thyroid
o Bone Metastasis
o Lymphoma
o Endocrine Tumors
o Other Therapeutic Applications

By Procedural Volume

• Diagnostic Procedures
o Spect Radiopharmaceuticals
o Pet Radiopharmaceuticals
• Therapeutic Procedures
o Beta Emitters
o Alpha Emitters
o Brachytherapy Isotopes

By Source

• Nuclear Reactors
• Cyclotrons

By End User

• Hospitals
• Ambulatory Surgical Centers
• Diagnostic Centers
• Cancer Research Institutes
• Others

Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends & Forecast to 2026

Enquire Here Get customization & check discount for report @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-radiopharmaceuticals-market

Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

This release was published on openPR.